Tyra Biosciences, a Carlsbad, Calif.-based company discovering and developing new small molecule therapies targeting acquired resistance in oncology, raised $50M in Series A financing.
The round was co-led by Alta Partners, RA Capital Management, Boxer Capital of Tavistock Group, and Canaan.
The company intends to use the funds to advance next-generation compounds targeting acquired resistance to current therapies towards clinical trials.
Led by Todd Harris, co-founder and CEO, and Daniel Bensen, co-founder and COO, and incubated by Alta Partners, Tyra Biosciences is a purpose-built company – with a founding team optimized for tackling this high-impact problem – aiming to develop very specific compounds targeting drug resistant cancer cells and populations.
The team also includes:
– Ronald V. Swanson, Ph.D., Chief Scientific Officer;
– Robert L. Hudkins, Ph.D., Vice President, Chemistry;
– Jane Arboleda, Associate Director of Cell Biology;
– Esther van den Boom, Chief Financial Officer;
– Jeffrey Hager, Ph.D., Scientific Advisor;
– William Hahn, M.D. Ph.D., Scientific Advisor; and
– Jason Sheltzer, Ph.D, Scientific Advisor.
The company’s board members are:
– Bob More, Chairman and Managing Director, Alta Partners;
– Isan Chen, M.D., Chief Medical Officer, Mirati Therapeutics;
– Gilla Kaplan, Ph.D., formerly at Gates Foundation, Rockefeller University, and Celgene;
– Jake Simson, Ph.D., Principal, RA Capital Management
– Sid Subramony, Ph.D., Vice President, Boxer Capital of Tavistock Group; and
– Nina Kjellson, General Partner, Canaan.